Rapport Therapeutics Inc
RAPP30.930USD
+0.310+1.01%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.47BMarket Cap
LossP/E TTM
More Details of Rapport Therapeutics Inc Company
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
Rapport Therapeutics Inc Info
Ticker SymbolRAPP
Company nameRapport Therapeutics Inc
IPO dateJun 07, 2024
CEOCeesay (Abraham N)
Number of employees69
Security typeOrdinary Share
Fiscal year-endJun 07
Address99 High Street
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02110
Phone18573218020
Websitehttps://www.rapportrx.com/
Ticker SymbolRAPP
IPO dateJun 07, 2024
CEOCeesay (Abraham N)
Company Executives of Rapport Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
737.20K
-0.79%
Dr. Steven M. (Steve) Paul, M.D.
Dr. Steven M. (Steve) Paul, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
477.64K
--
Mr. David Bredt, M.D., Ph.D.
Mr. David Bredt, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
401.14K
-2.07%
Ms. Cheryl Gault
Ms. Cheryl Gault
Chief Operating Officer
Chief Operating Officer
171.93K
--
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Chief Financial Officer
Chief Financial Officer
10.00K
--
Dr. Ramiro (Raymond) Sanchez, M.D.
Dr. Ramiro (Raymond) Sanchez, M.D.
Independent Director
Independent Director
--
--
Dr. James I. Healey, M.D., Ph.D.
Dr. James I. Healey, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert J. (Rob) Perez
Mr. Robert J. (Rob) Perez
Independent Director
Independent Director
--
--
Ms. Wendy B. Young, Ph.D.
Ms. Wendy B. Young, Ph.D.
Independent Director
Independent Director
--
--
Mr. Reid Huber, Ph.D.
Mr. Reid Huber, Ph.D.
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
737.20K
-0.79%
Dr. Steven M. (Steve) Paul, M.D.
Dr. Steven M. (Steve) Paul, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
477.64K
--
Mr. David Bredt, M.D., Ph.D.
Mr. David Bredt, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
401.14K
-2.07%
Ms. Cheryl Gault
Ms. Cheryl Gault
Chief Operating Officer
Chief Operating Officer
171.93K
--
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Chief Financial Officer
Chief Financial Officer
10.00K
--
Dr. Ramiro (Raymond) Sanchez, M.D.
Dr. Ramiro (Raymond) Sanchez, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 30
Updated: Sun, Nov 30
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Third Rock Ventures, LLC
17.00%
Fidelity Management & Research Company LLC
14.51%
ARCH Venture Partners
7.82%
Capital International Investors
7.14%
Cormorant Asset Management, LP
6.70%
Other
46.82%
Shareholders
Shareholders
Proportion
Third Rock Ventures, LLC
17.00%
Fidelity Management & Research Company LLC
14.51%
ARCH Venture Partners
7.82%
Capital International Investors
7.14%
Cormorant Asset Management, LP
6.70%
Other
46.82%
Shareholder Types
Shareholders
Proportion
Investment Advisor
40.55%
Venture Capital
32.66%
Hedge Fund
14.37%
Investment Advisor/Hedge Fund
10.63%
Individual Investor
4.65%
Research Firm
4.19%
Bank and Trust
0.86%
Private Equity
0.85%
Pension Fund
0.04%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
166
42.95M
90.12%
+1.16M
2025Q2
154
43.38M
118.86%
+3.70M
2025Q1
149
47.96M
131.36%
+9.87M
2024Q4
117
46.27M
126.51%
+9.23M
2024Q3
91
39.09M
106.87%
+12.18M
2024Q2
48
37.49M
102.49%
+37.49M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Third Rock Ventures, LLC
8.10M
17.58%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
5.47M
11.87%
-11.84K
-0.22%
Jun 30, 2025
ARCH Venture Partners
3.73M
8.09%
--
--
Jun 30, 2025
Capital International Investors
2.60M
5.64%
--
--
Jun 30, 2025
Cormorant Asset Management, LP
2.94M
6.38%
--
--
Jun 30, 2025
Sofinnova Investments, Inc
1.95M
4.22%
-48.02K
-2.41%
Sep 12, 2025
Johnson & Johnson Innovation-JJDC, Inc.
2.50M
5.42%
--
--
Jun 30, 2025
Goldman Sachs & Company, Inc.
1.24M
2.68%
-9.28K
-0.75%
Jun 30, 2025
The Vanguard Group, Inc.
1.11M
2.4%
-4.08K
-0.37%
Jun 30, 2025
Baker Bros. Advisors LP
550.09K
1.19%
+550.09K
--
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.76%
iShares Neuroscience and Healthcare ETF
0.84%
ALPS Medical Breakthroughs ETF
0.43%
Invesco Nasdaq Biotechnology ETF
0.1%
iShares Micro-Cap ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.1%
Avantis US Small Cap Equity ETF
0.06%
iShares Biotechnology ETF
0.06%
Vanguard US Momentum Factor ETF
0.04%
iShares Russell 2000 Value ETF
0.03%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.76%
iShares Neuroscience and Healthcare ETF
Proportion0.84%
ALPS Medical Breakthroughs ETF
Proportion0.43%
Invesco Nasdaq Biotechnology ETF
Proportion0.1%
iShares Micro-Cap ETF
Proportion0.1%
ProShares Ultra Nasdaq Biotechnology
Proportion0.1%
Avantis US Small Cap Equity ETF
Proportion0.06%
iShares Biotechnology ETF
Proportion0.06%
Vanguard US Momentum Factor ETF
Proportion0.04%
iShares Russell 2000 Value ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Rapport Therapeutics Inc?
The top five shareholders of Rapport Therapeutics Inc are:
Third Rock Ventures, LLC holds 8.10M shares, accounting for 17.58% of the total shares.
Fidelity Management & Research Company LLC holds 5.47M shares, accounting for 11.87% of the total shares.
ARCH Venture Partners holds 3.73M shares, accounting for 8.09% of the total shares.
Capital International Investors holds 2.60M shares, accounting for 5.64% of the total shares.
Cormorant Asset Management, LP holds 2.94M shares, accounting for 6.38% of the total shares.
Third Rock Ventures, LLC holds 8.10M shares, accounting for 17.58% of the total shares.
Fidelity Management & Research Company LLC holds 5.47M shares, accounting for 11.87% of the total shares.
ARCH Venture Partners holds 3.73M shares, accounting for 8.09% of the total shares.
Capital International Investors holds 2.60M shares, accounting for 5.64% of the total shares.
Cormorant Asset Management, LP holds 2.94M shares, accounting for 6.38% of the total shares.
What are the top three shareholder types of Rapport Therapeutics Inc?
The top three shareholder types of Rapport Therapeutics Inc are:
Third Rock Ventures, LLC
Fidelity Management & Research Company LLC
ARCH Venture Partners
Third Rock Ventures, LLC
Fidelity Management & Research Company LLC
ARCH Venture Partners
How many institutions hold shares of Rapport Therapeutics Inc (RAPP)?
As of 2025Q3, 166 institutions hold shares of Rapport Therapeutics Inc, with a combined market value of approximately 42.95M, accounting for 90.12% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -28.75%.
What is the biggest source of revenue for Rapport Therapeutics Inc?
In --, the -- business generated the highest revenue for Rapport Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
